Skip to content

The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy

The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06041399
Enrollment
1400
Registered
2023-09-18
Start date
2012-02-01
Completion date
2025-01-02
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Peripheral Neuropathy

Keywords

Diabetic Peripheral Neuropathy, electromyography, blood parameters

Brief summary

The goal of this observational study is to explore the relationship between related blood indicators and diabetic peripheral neuropathy.

Detailed description

This is a multi-center(about five), randomized, double-blind, placebo-controlled clinical trial with over 1000 subjects.Clinical data were collected by consulting the patient's electronic history. The data included demographic information, blood biochemical markers and electromyography. All participants provided their written informed consent to participate in this study.The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University(KY-2022-R009).

Interventions

DRUGhypoglycemic Agents(metformin)

patients treated with hypoglycemic Agents(metformin)

DRUGlipid-lowering drug(Statin)

patients treated with lipid-lowering drug(Statin)

Sponsors

First Affiliated Hospital of Wenzhou Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* patients who had undergone nerve conduction examination by electromyography(EMG).

Exclusion criteria

* pregnancy and lactation; chronic liver disease, kidney disease, arrhythmias, malignant diseases, severe respiratory diseases, heart failure, and acute infections; * patients with alcohol abuse; history of Autoimmune liver disease, liver disease or abnormal liver function at baseline; * parathyroid diseases (including hyperthyroidism and hypothyroidism); * pancreatitis, pancreatectomy or any transplant; * patients with malignancy and any serious concomitant disease limit the existence of life expectancy

Design outcomes

Primary

MeasureTime frameDescription
the severity of diabetic peripheral neuropathyFrom admission to discharge, up to 1 weekThe nerve conduction examination was conducted at a room temperature of 24℃, with the legs warmed using an electric heating pad for at least 10 minutes to achieve a skin temperature of 32-35℃. The nerve conduction velocities and nerve conduction amplitudes were measured for both sides of the upper and lower limbs, including motor and sensory branches of the median nerve; motor and sensory branches of the ulnar nerve; motor branch of peroneal nerve; motor branch of the tibial nerve; sensory branch of the superficial peroneal nerve. In addition, both sides of the tibial nerve F-wave were recorded, and the lower one was regarded as the final F-wave. Slowed/blocked nerve conduction was defined as more than 2.5 standard deviation below the control nerve conduction threshold. Nerve conduction is defined as abnormal when two or more nerve abnormalities are detected.
the presence of diabetic peripheral neuropathyFrom admission to discharge, up to 1 weekWhen any of the elements of the screening process -- symptoms, signs, or abnormal nerve conduction parameters --was abnormal, medical records would be scrutinized to see if these participants had accepted a previous diabetic peripheral neuropathy diagnosis by a specialist.

Countries

China

Contacts

Primary ContactBinbin Deng, Doctor
dbinbin@aliyun.com86-13695720610

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026